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Introduction
Advances in human molecular genetics have greatly
enhanced our ability to identify the genetic basis for many
human diseases, including the autoimmune diseases.
Characterization of the genetic determinants requires the
evaluation of polymorphism in families and populations to
detect the relationship between individual variants and
disease phenotypes. Such activities originally relied on
measuring polymorphism at the protein level. The exten-
sive literature on human leukocyte antigen (HLA) and
disease began with antibodies that defined allelic variation
with sera that recognized individual polymorphisms, now
understood to be expressed in a host of HLA molecules
that regulate the immune response.
This approach has recently become more general as DNA
variants can be characterized systematically and can be
correlated with disease. The first sets of polymorphisms
available for such studies were variable repeats spread
throughout the genome. Typing polymorphisms in DNA
has always been a limiting factor in such studies and, for
the first time, the identification of variable number of
tandem repeat sequences allowed highly variable repeat
sequences to be readily typed using Southern blots [1].
However, the infrequency of such complex repeats limited
their utility and, although they have been informative in
terms of describing individual genetic diversity, their role in
identifying disease-related genetic variation has been
limited.
The next revolution in genetic variation scoring arose
directly from the introduction of another methodology; the
polymerase chain reaction. This methodology allowed the
systematic characterization of smaller dinucleotide and
trinucleotide repeats throughout the genome. These could
be easily identified, were highly polymorphic, and could be
readily mapped at high density throughout the human
genome. These repeats provided the first mechanism for
searching genome wide for evidence of genetic linkage
and disease. Their frequency was not sufficiently high,
however, to allow their application in population-based
studies of human disease that had proved so productive
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when the HLA region had been studied using antibodies.
Despite this, the application of these markers became the
basis for whole genome linkage studies that have provided
information, in family samples, of the localization of a large
number of disease genes in autoimmune disease and
other complex traits [2].
The most significant development to date in the molecular
study of disease genetics has emerged from the availabil-
ity of the human genome sequence. This data provided the
template from which to generate extensive amounts of
information on single nucleotide variants. Several impor-
tant advantages emerge from the availability of such single
nucleotide polymorphisms (SNPs). These are by far the
commonest form of polymorphism within the genome.
These variants will account for the vast majority of poly-
morphism responsible for human disease. The variation
occurs in both coding and noncoding sequences at a fre-
quency of approximately 1 per 1000 base pairs. The
extent of variation is limited, however, by the complex rela-
tionship between these variants, reflecting population
history, recombination hot spots, and selection.
Although large numbers of such polymorphisms had been
previously described, both within genes and in intervening
sequences, the systematic generation of very large
numbers of such variants at high density throughout the
genome was necessary if these variants were to be used
to look systematically for disease-related genetic variation.
The generation of this large set of SNPs has been accom-
panied by methodology for typing such variation efficiently.
The binary nature of these polymorphisms makes them
much easier to type in an automated fashion. As this
methodology becomes more inexpensive and efficient, it
should be possible to catalogue the polymorphisms that
exist at a very large number of sites in individuals with and
without disease, and hence should be possible to derive
information about the genetic susceptibility factors that
contribute to many human diseases.
This review will consider the role of these SNPs in
mapping human disease related to DNA variation; in par-
ticular, the use of SNP typing to characterize haplotypes
throughout the genome, and the use of linkage disequilib-
rium (LD) patterns to find changes that relate to pheno-
types. It will also consider how such information should be
used to study disease in association strategies and will
highlight the basis for current failings of this approach.
The SNP map of the human genome
Although there is extensive data to suggest that single
nucleotide variation exists within the human genome at a
frequency of approximately 1 per 1000 base pairs [3], only
recently has extensive sequencing and resequencing of the
genome provided large sets of SNPs to study [4–6]. The
publication reporting the identification of 1.42 million SNPs
in 2001 provided the necessary information to study their
relationship to each other across the genome [4].
The SNP Consortium (TSC) has contributed the largest
set of SNPs identified by shotgun sequencing of
genomic fragments [4]. These were obtained using an
ethnically diverse panel of 24 individuals. Other large
sets of SNPs have been derived from analysis of overlap
regions of the human genome sequence derived from
bacterial artificial chromosome-derived and P1-derived
artificial chromosome sequences obtained during the
human genome project. The allele frequency of these
SNPs suggests that 82% are polymorphic at frequen-
cies of 10% or greater in at least one ethnic population.
Twenty-seven percent had an allele frequency >20% in
the three ethnic groups studied (European, African-
American and Chinese).
On average, the TSC SNPs were most evenly distributed
and were found every 3.05 kb. The SNP density was
found to be relatively even across most chromosomes
except for the X and Y chromosomes, where there were
lower rates of heterozygosity. This was explained by the
lower effective population size associated with the X chro-
mosome (hemizygosity in males means that the effective
population is three-quarters that of the autosomes) and
with the Y chromosome, which has a lower effective popu-
lation size but a higher mutation rate at male meiosis. The
pseudoautosomal region of the Y chromosome known to
recombine with the X chromosome shows very high levels
of heterozygosity as expected, while the nonrecombining
region shows very low levels.
The extent of polymorphism is potentially driven by a
number of factors. The population history would undoubt-
edly be important, in particular the timing of individual
mutations, the population admixture and recombination
rates, as will balancing selection in some cases. Regions
of very high heterozygosity were also detected, including
the HLA region on chromosome 6. We already know a
great deal about this region and the role of balancing
selection in establishing and maintaining polymorphisms in
the HLA loci. It will be interesting to see whether other
regions of high heterozygosity relate to genomic regions
where selection and or recombination rates have played a
dominant role.
LD patterns and haplotypes
With the availability of genome wide sets of SNPs, it
becomes possible to search the genome for genetic varia-
tion that accounts for human disease and other traits
[7,8]. No technology is currently available to type the full
set of SNPs in population samples, nor indeed is such a
comprehensive set of markers available. Of the marker
sets available of polymorphic sequences, only a fraction of
functional disease-related SNPs are currently available.S275
If each genetic polymorphism added independently to the
variation, then the total set of variable chromosomes would
be huge and the prospect of defining disease-related
changes in the short term would be small. Fortunately, not
all genetic variants operate independently. Alleles that lie
close to each other on the chromosome are often found
together more often than one would predict if they were
segregating independently. This results from a variety of
mechanisms but is most commonly the result of the histori-
cal development of mutations on a haplotype. New variants
always occur in the context of already existing variants.
These allelic associations will break down over time but that
will depend on recombination between adjacent polymor-
phisms and, in some cases, selection. Because of the time
frame necessary to separate these associations, many
ancestral haplotypes exist widely throughout the genome.
The relationship between polymorphic markers on the chro-
mosome is referred to as linkage disequilibrium (LD) [9].
Those interested in the genetics of autoimmune disease
will be familiar with the concept of LD as it exists within
the HLA complex. The earliest studies of the relationship
between autoimmune disease and HLA alleles suggested
associations with HLA class I loci. As typing improved, it
became evident that many of these associations related
instead to class II alleles that reside several hundreds of
kilobases away from the class I region. Fortunately for
those using the HLA as a locus for disease genetics, the
level of polymorphism in this region is extraordinarily high
and there is extensive LD across the region. So, for
example, the original association between HLA B8 and
type I diabetes has now been shown to reflect the
causative mutations within the HLA DQ region [10].
Some of the ancestral haplotypes extend over the entire
region and show very high levels of conservation (i.e. A1,
B8, DR3). This LD allowed the region to be associated
with a large number of autoimmune diseases and, in
some cases, even diseases that are nonimmune in nature
but where genetic variation occurred on top of the exist-
ing ancestral haplotype. The association of the mutation
in the HFE protein responsible for haemochromatosis
with the HLA A3 haplotype is a clear example of this
pattern of LD [11]. The rich disease gene mining that
occurred by studying the HLA succeeded only because
of the strong LD in the region, because none of the poly-
morphisms serologically studied initially were the variants
responsible for disease.
Little is known about the mechanisms responsible for the
persistent and strong LD in the HLA region. We do know
that the alleles in the region are the subject of strong bal-
ancing selection. Clear evidence now exists for the role of
these alleles in determining the response to infectious
pathogens that have exerted powerful selective forces on
human populations. For example, the severity of malaria
infection seems to be determined by the presence of
alleles of the HLA loci [12]. Recombination in this HLA
region, detected in family studies, suggests that
crossovers occur at a rate (2 cM/Mb) that is somewhat
higher than the average around the genome.
Recent studies have attempted to study in detail the
pattern of LD within a small portion of the MHC region
[13]. In the region between DNA and TAP2, a region of
approximately 200 kb, there are three regions of very
strong LD that are broken up into discreet regions where
LD is broken down. Sperm typing has been used to define
the precise regions of meiotic recombination, and this
revealed that such crossovers are highly clustered into five
recombinational hot spots [14]. One of these hot spots
(DNA 3) has a recombination frequency of 140 cM/Mb. In
total, 94% of the crossovers recorded occurred within hot
spots, although no sequence motifs defining such regions
were recognized. Detailed analysis of this region by
several groups has therefore defined regions of LD
extending across distances of up to 100 kb that are inter-
rupted by short recombinational hot spots [15,16].
Although much is known about patterns of LD within the
MHC, the important outstanding question for human genet-
ics is whether the same pattern of LD exists elsewhere in
the genome. The large, dense set of SNPs now available is
the resource necessary to undertake such studies. Predic-
tions of LD across the genome have been unhelpful, largely
because it is widely recognized that the patterns are het-
erogeneous. Studies of individual regions have suggested
that, typically, LD often extends 60 kb from common alleles
when tested with islands of sequences leading out from
such common SNPs. In characterizing 19 such regions
[14], the pattern of LD was greater than expected and
there was evidence of significant variation from region to
region. LD declined as distance grew from the central
allele. Interestingly, this study established a correlation
between the recombination rate within a genomic segment
and the extent of LD in that region.
Although such studies provide some indication of what may
be evident on a genome wide basis, more robust data
comes from systematic approaches to haplotype mapping
using large sets of markers across whole chromosomes.
Such marker sets are widely available as a result of the SNP
map. The first of these to be systematically tested covers
chromosome 22 with a set of 1504 SNPs studied in the
CEPH reference families (Dawson E et al., manuscript sub-
mitted). Again, significant heterogeneity in levels of LD were
seen, with large regions >700 kb showing extensive LD
while other regions revealed little evidence of LD, even
between adjacent high-frequency alleles. Systematic study
of LD on chromosome 21 has similarly been performed
using radiation hybrids and oligonucleotide arrays, and it
has revealed similar areas of limited haplotype diversity [17].
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It would appear, therefore, that the situation seen in the
MHC region with regard to LD is not unique and that
extensive regions of LD exist throughout the genome, but
that significant heterogeneity also exists between regions.
A central, remaining question is how such regions occur
and are maintained. Population history remains important
and large areas of LD may reflect the lack of opportunity
for recombination because the time frame has been short
since the founder haplotype occurred or since an evolu-
tionary bottleneck occurred. As in the MHC, the role of
recombination rates and sites of recombinational activity
may also be important. Selection also cannot be dis-
counted in this process. Particularly in regions where gene
products are heavily selected and potentially interactive,
this may determine the coexistence of neighbouring
alleles. Little is known about the sequences associated
with high recombination rates, nor is there any good data
on the sequences most associated with high LD.
Importantly, these data suggest that haplotypes are wide-
spread throughout the genome and, whatever their mech-
anisms, may be valuable tools for moving into association
studies in common disease. By carefully choosing markers
from regions where LD is strong, it should be possible to
undertake anonymous association strategies with the
minimal number of SNPs. This approach should make non-
hypothesis-based association strategies viable in the short
term, allowing genetic effects such as those seen in the
HLA region to be readily recognized and validated.
The use of such SNP tools holds great promise, but is not
without its own complications. Disease-related genomic
regions will be easier to detect in regions of strong and
extensive LD. Once detected, however, it becomes chal-
lenging to detect the exact locus and polymorphism that
accounts for disease susceptibility. This obstacle remains
an issue for most HLA disease associations because the
strong LD makes difficult the characterization of the role of
any single polymorphism in the region where multiple vari-
ants contribute identical genetic information. This problem
has arisen repeatedly in the HLA and has also been seen in
other regions, such as the region around the insulin locus
on chromosome 11 in the study of type I diabetes [18] and,
more recently, in the study of the role of the cytokine
cluster on 5q21 in Crohn’s disease [19]. So although the
presence of strong LD facilitates the identification of
disease-associated regions, it makes the characterization
of disease mutations or polymorphisms more difficult.
Another important issue to consider is that patterns of LD
vary significantly between different population groups. This
is potentially a mechanism whereby LD can be broken
down to allow disease polymorphisms to be mapped. Such
an approach was used to describe the role of individual
loci in type I diabetes susceptibility utilizing the differential
HLA haplotypes seen in Africa and Western Europe [20].
Ethnic heterogeneity in LD, however, also proves challeng-
ing in interpreting disease association data. Any bias in
ethnic sampling between patients and controls can give
rise to inappropriate assumptions about responsible loci
and levels of risk that they confer.
The pattern of LD that is determined by population history
can also be seriously influenced by the use of founder
populations. The advantages of such approaches have
been emphasized for studying complex traits. Populations
with strong founder effects have obvious advantages in
that they share significant genetic determinants and hence
the locus and allelic heterogeneity that complicate the
study of these diseases are reduced.
Population history determined the benefits derived from
LD. When Eaves et al. characterized Finnish and Sardinian
isolates, and compared their LD pattern in a region of
chromosome 18 with Western European mixed popula-
tions, the levels of LD were not significantly different [21].
They suggest that this may reflect the entry of individual
polymorphisms into the population through a number of
different founders. The history of genetic isolates is there-
fore crucial for understanding the LD achieved.
Rare polymorphisms are likely to have arisen recently or
from a single founder. If the variant is recent then the LD is
probably strong and will represent the relatively short
recombinational history of the haplotype. When the poly-
morphism is found at a higher frequency, it may have arisen
from multiple founders and one would not expect the LD to
be dramatically increased. The LD around a common
variant will be increased only if it has arisen on a founder
haplotype from a limited number of individuals, and hence
this is likely to arise only in a small, isolated population.
Overall, therefore, the role of founder populations in facili-
tating the search for common disease genes and polymor-
phisms is complex and the utility relates as much to the
population history and age of the variants as it does to the
presence of the concept of founders in the population.
Association strategies using SNPs in common
disease
One of the most important applications that will arise from
the availability of a large number of SNPs and LD on
haplotype maps around the genome is the ability to sys-
tematically undertake association studies directed at iden-
tifying genetic determinants for common disease [22].
Association studies have been enormously successful at
identifying some of the major loci involved in common
disease. Associations between HLA alleles, first deter-
mined by serology and more recently by DNA typing, have
identified a role for HLA gene products in determining sus-
ceptibility to a range of autoimmune diseases, including
type I diabetes, rheumatoid arthritis, coeliac disease, multi-
ple sclerosis and ulcerative colitis.
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The success of these studies has, however, provided a
false sense of security around the use of association
strategies in mapping disease genes. The history of asso-
ciation studies in autoimmune disease since the identifica-
tion of HLA associations has been limited. Many
associations have been identified and then proven not to
be reproducible in subsequent studies. Association strate-
gies have therefore developed a bad reputation for pro-
ducing false-positive results. Nevertheless, it is clear that,
when properly applied, association strategies have poten-
tially much greater power to detect genetic contributions
to common complex diseases than that available using
linkage studies. Not only is the statistical power to detect
the genetic contribution to disease greater in association
studies [23], it is also an essential component of the proof
necessary to implicate a DNA variant within a linkage
region as mediating disease susceptibility or pathogenesis.
An analysis of the potential pitfalls linked with association
strategies is helpful, particularly at this time when they are
likely to be more widely applied with the increasingly avail-
able SNP resources. First and foremost among the prob-
lems surrounding association strategy is the failure to have
a sufficiently large sample size to produce convincing
statistical support for a hypothesis. Few, if any, genetic loci
yet to be identified in autoimmune disease will have the
strength of HLA associations. Many of the genetic determi-
nants of autoimmune disease will be contributing relative
risks of between 2 and 4; as a result, large numbers of
patients will need to be studied to identify these effects.
These effects will also be diluted by the considerable het-
erogeneity that may underlie these diseases and by the fact
that most genetic associations originally described are
unlikely to be primary associations, but simply represent LD
with the functional DNA variant responsible for disease.
Both locus and allelic heterogeneity may add complexity to
this formula. Together these confounding factors mean that
large sample sizes (many hundreds of cases and controls)
need to be studied to detect significant effects.
Population stratification is often identified as a cause for
false-positive association studies. Although this has often
been suggested, it has seldom been documented with any
degree of rigour. Nevertheless, it is important to identify
control populations that most properly represent samples
for comparison with the disease group. Several strategies
can be applied for identifying control populations [22].
Age-matched and sex-matched controls from similar
ethnic backgrounds will provide some degree of confi-
dence in variation in allele frequencies between patients
and controls. Alternatively, sampling widely from diverse
ethnic populations may provide information on the normal
range of allele frequencies in diverse population groups.
Family-based controls provide an opportunity to reduce
population stratification [24]. Should the disease popula-
tion vary substantially from these, it provides confidence
that the allele may be genuinely contributing to the
disease state. Multiple testing and repeated subgroup
analysis are conventional errors in methodology often seen
in association strategies in human disease. Such strate-
gies have proved to be misleading in epidemiological
studies of all kinds and, increasingly, have proved to be
the cause of false-positive data in genetic association
studies. Any analysis of subsets of the disease population
gives rise to serious statistical problems and can only be
corrected by large and robust replicated studies, where
the hypothesis is defined before the study is undertaken.
The availability of a large number of SNPs has also given
rise to a problem associated with multiple testing of differ-
ent allelic variants in case and control populations. At its
worst, this problem is seen in ‘whole genome association’
strategies whereby very large numbers of SNPs are typed
in disease and control populations. For example, if 1000
random SNPs are utilized for such association studies,
one would expect 50 associations to be found at a signifi-
cance level of P < 0.05. Given the issues of power already
discussed, this strategy on its own is clearly fraught with
difficulties. The significance of an association is obviously
enhanced by the characterization biologically of an impor-
tant candidate in disease pathogenesis or by the availabil-
ity of previous data that points to a role for a specific
polymorphism or gene in disease. Again, however, post
hoc identification of candidates (e.g. in the region of
linkage) can be a misleading approach, which carries with
it risks of data overinterpretation.
The availability of haplotype maps around the genome pro-
vides perhaps the best opportunity for large-scale associ-
ation strategies in autoimmune disease and other common
disorders [25–27]. Based on currently available data, it
would appear that some significant component of the
genome can be analysed by the relatively small number of
markers covering the areas where LD is strong and the
number of haplotypes is limited. Within carefully controlled
studies it may therefore be possible to eliminate, by asso-
ciation strategies, large segments of the genome from
contributing any significant degree of risk to complex dis-
eases, while other regions, where strong disequilibrium
exists, may be identified for future analysis.
While this strategy has the potential of ruling in or ruling
out very large segments of the genome for genetic analy-
sis, the regions that have been identified through LD
mapping as having a role in common disease provide
significant challenges for the characterization of individual
disease variants. Regions where LD is strong are
extremely difficult to break down to the level of single DNA
variants. This is particularly evident in regions such as the
HLA, where the search for individual DNA variants respon-
sible for disease associations continues to challenge
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immunogeneticists. Nevertheless, this appears to be a
strategy that will yield important association data, at least
in the short term.
Concluding remarks
The availability of a large number of SNPs widely dis-
persed throughout the genome is likely to greatly acceler-
ate disease gene hunting in autoimmunity. SNPs are thus
not always independent, and the use of LD may facilitate
the systematic search for associations. Before this
happens, however, it is important to be clear about the
methodological issues that have limited the effectiveness
of previous simple association strategies. Only then will
definitive genetic association data emerge.
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